Herpes simplex vaccine - Xenova

Drug Profile

Herpes simplex vaccine - Xenova

Alternative Names: DISC HSV; DISC HSV-1; DISC HSV-2; GW 419458; TA HSV

Latest Information Update: 17 Jan 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenova Group
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 17 Jan 2005 The DISC-HSV Vector platform has been licensed to Oxxon Therapeutics worldwide
  • 15 Oct 2001 The agreement with GSK to co-develop TA HSV will be terminated effective January 2002
  • 15 Oct 2001 Discontinued-II for Herpes simplex virus infections in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top